Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Mackay
Helen J
HJ
Princess Margaret Phase II Consortium, Toronto, Canada. helen.mackay@uhn.on.ca
Hirte
Hal
H
Colgan
Terrence
T
Covens
Al
A
MacAlpine
Katrina
K
Grenci
Pamela
P
Wang
Lisa
L
Mason
Jaqueline
J
Pham
Pnu-An
PA
Tsao
Ming-S
MS
Pan
James
J
Zwiebel
James
J
Oza
Amit M
AM
D000107:Acetylation / Q000187:drug effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006657:Histones / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat